Auxly Cannabis Group Inc is one cannabis stock on the OTCQB that many investors see having a big future. The Company is well position with over $200 million in the treasury and expected production capacity of 160,000 kg by 2021. Auxly has financed much of its growth through dilution and as the Company is not yet generating revenues the stock price has lagged creating what many see as a significant opportunity.
Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) is a vertically integrated cannabis company currently sitting on a war chest of $295 million. The Company’s vision is to become the first and foremost streaming enterprise in the cannabis industry and to provide alternative financing solutions for smaller licensed producers. Auxly is the brainchild of Chuck Rifici – ‘Godfather of Canadian weed’ founder of Canopy Growth, former CEO of Tweed Marijuana Inc, and former CFO of the Liberal Party of Canada. Auxly has licensing and streaming deals with at least 15 licensed producers listed here.
Auxly also has an 80% stake in Montevideo, Uruguay based Inverell, a federally licensed “Cannabis Operator” for the large-scale outdoor production of hemp plants for CBD extraction. Led by a seasoned operator, Dr Raul Urbina, founder and CEO of Stevia One, that became one of the lowest cost producers of stevia in the world. Inverell has 16 hectares of plants in the ground with expansion capacity for an additional 574 hectares. Inverell gives Auxly a diversified source of low-cost CBD production for the Company’s international distribution channels. It also gives Auxly a foothold in the Uruguays cannabis market which aims to be a dominate player globally.
In 2018 Auxly acquired Dosecann Inc. a late-stage “Licensed Dealer” applicant pursuant to the Narcotic Control Regulations. Located in the biotech hub of Charlottetown, Prince Edward Island, Dosecann is currently completing the buildout of a 42,000 square foot facility, purpose-built for the research, development, extraction, formulation, filling and packaging of cannabis-based products. Upon receipt of regulatory approval, Dosecann will leverage its state-of-the-art facility to begin developing a range of value added cannabis-based products for the Company and its streaming partners to ultimately be sold to medical cannabis patients and, upon approval, into the natural health product and adult-use cannabis markets.
To Find out the inside Scoop on Auxly Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Last year Auxly announced a strategic investment and commercial rights agreement with Kaneh Bosm. The Transaction provides Auxly access to a significant and established portfolio of international cannabis licenses, assets and distribution networks. As a result of the Transaction, Auxley believes that it has substantially accelerated its entry into numerous international cannabis markets and partnered with an ambitious team focused on future growth. As part of the transaction, Kaneh Bosm changed its name to ICC International Cannabis Corp. Kaneh Bosm, through its subsidiaries, has a number of agreements and licenses in place related to pharmaceutical distribution, wholesale importation, research and development, cultivation, production, storage, and exportation of cannabis and cannabis derivatives. In particular, Kaneh Bosm has agreements in place to supply a European-based pharmaceutical distributor with a network of 35,000 pharmacies in 16 countries, in addition to working interests in industrial hemp licenses in Greece and wholly-owned licenses to cultivate, produce, distribute, store, and export cannabis in Colombia, the Kingdom of Lesotho, and Denmark.
On February 13 Auxly announced the appointments of Brian Schmitt as Chief Financial Officer, Jason Sonshine as Vice President, Strategy, and Carla Nawrocki as Vice President, Investor Relations of the Company. Chuck Rifici noted “We are delighted that Brian, Jason and Carla have joined the Auxly family and look forward to their insight and contributions as we continue to execute on our strategic plan. We are very pleased with the strength of the management team that we’ve assembled here at Auxly.”
This comes after Auxly announced the termination of the definitive agreement dated March 3, 2018 between the Company and FV Pharma Inc., a wholly-owned subsidiary of FSD Pharma Inc. governing the joint venture between the parties.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $354 million market valuation Auxly is sitting on a war chest of $234 million, and is debt free. Led by cannabis visionary Chuck Rifici, Auxly has quickly attracted a leadership team of industry first movers, enterprising visionaries and deep-experience specialists. Auxly has licensing and streaming deals in place with at least 15 licensed producers and is well on their way to being one of the biggest cannabis producers on the planet. Auxly has financed much of its growth through dilution and as the Company is not yet generating revenues the stock price has lagged creating what many see as a significant opportunity. We will be updating on Auxly when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Auxly.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in Auxly either long or short and we have not been compensated for this article.